Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iovance Biotherapeutics ( (IOVA) ) has issued an update.
On July 15, 2025, Iovance Biotherapeutics announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6, 2025. Ms. Roche, who brings over 30 years of experience in the biotech and life sciences industry, will replace Matthew W. Rosinack. Her extensive background in executive financial leadership and product launches is expected to be invaluable as Iovance focuses on revenue growth and advancing its mission of developing novel therapies for cancer patients. This strategic appointment is seen as a significant step for Iovance as it navigates its first commercial launch and aims to strengthen its position in the biotechnology industry.
The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
Iovance Biotherapeutics’ overall score is impacted by its unprofitability and operational inefficiencies, despite revenue growth. Technical analysis shows moderate signals but valuation remains poor. Earnings call and corporate events offer some positive outlook with significant challenges.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. The company aims to be a global leader in this field, pioneering a transformational approach to cancer treatment by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells. Iovance’s TIL platform has shown promising clinical data across multiple solid tumors, and its product Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication.
Average Trading Volume: 13,793,357
Technical Sentiment Signal: Sell
Current Market Cap: $624.5M
For a thorough assessment of IOVA stock, go to TipRanks’ Stock Analysis page.